Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07466160) titled 'A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors' on March 8.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
Condition:
Solid Tumor
Intervention:
Drug: 7MW3711
Drug: JS207
Drug: Cisplatin
Recruitment Status: Recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: February 11, 2026
Target Sample Size: 280
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT0746...